Einsele, Hermann

Human NK Cells Display Important Antifungal Activity against Aspergillus fumigatus, Which Is Directly Mediated by IFN-γ Release

Bouzani, M., Ok, M., McCormick, A., Ebel, F., Kurzai, O., Morton, C. O., Einsele, H., & Loeffler, J. (2011) · The Journal of Immunology

Immune Cell Function and InteractionAntifungal resistance and susceptibility

Cited by 127

Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus

Beck, O., Topp, M. S., Koehl, U., Roilides, E., Simitsopoulou, M., Hanisch, M., Sarfati, J., Latgé, J. P., Klingebiel, T., Einsele, H., et al. (2006) · Blood

Antifungal resistance and susceptibilityT-cell and B-cell Immunology

Cited by 127

Human regulatory T cells are selectively activated by low‐dose application of the CD28 superagonist TGN1412/TAB08

Tabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T. (2014) · European Journal of Immunology

T-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Cited by 97

Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells

Staab, A., Loeffler, J., Said, H. M., Diehlmann, D., Katzer, A., Beyer, M., Fleischer, M., Schwab, F., Baier, K., Einsele, H., et al. (2007) · BMC Cancer

Cancer, Hypoxia, and MetabolismRadiation Therapy and Dosimetry

Cited by 89

Proteome Analysis Reveals the Conidial Surface Protein CcpA Essential for Virulence of the Pathogenic Fungus Aspergillus fumigatus

Voltersen, V., Blango, M. G., Herrmann, S., Schmidt, F., Heinekamp, T., Strassburger, M., Krüger, T., Bacher, P., Lother, J., Weiss, E., et al. (2018) · mBio

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 71

IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma

Barrio, S., Munawar, U., Zhu, Y. X., Giesen, N., Shi, C.-X., Viá, M. D., Sanchez, R., Bruins, L., Demler, T., Müller, N., et al. (2020) · Haematologica

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 67

Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study

Topp, M. S., Duell, J., Zugmaier, G., Attal, M., Moreau, P., Langer, C., Kroenke, J., Facon, T., Einsele, H., & Munzert, G. (2018) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 55

Combined targeting of MEK/MAPK and PI 3 K/Akt signalling in multiple myeloma

Steinbrunn, T., Stühmer, T., Sayehli, C., Chatterjee, M., Einsele, H., & Bargou, R. C. (2012) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsPI3K/AKT/mTOR signaling in cancer

Cited by 49

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)

Krönke, J., Kuchenbauer, F., Kull, M., Teleanu, V, Bullinger, L., Bunjes, D., Greiner, A., Kolmus, S., Köpff, S., Schreder, M., et al. (2017) · Leukemia

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 46

Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium

Lupiañez, C. B., Canet, L. M., Carvalho, A., Alcazar-Fuoli, L., Springer, J., Lackner, M., Segura-Catena, J., Comino, A., Olmedo, C., Ríos, R., et al. (2016) · Infection and Immunity

Antifungal resistance and susceptibilityImmunodeficiency and Autoimmune Disorders

Cited by 42

Hypoxia-inducible factor 1α modulates metabolic activity and cytokine release in anti- Aspergillus fumigatus immune responses initiated by human dendritic cells

Fliesser, M., Morton, C. O., Bonin, M., Ebel, F., Hünniger, K., Kurzai, O., Einsele, H., & Löffler, J. (2015) · International Journal of Medical Microbiology

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 38

Immunomodulation as a Therapy for Aspergillus Infection: Current Status and Future Perspectives

Lauruschkat, C. D., Einsele, H., & Loeffler, J. (2018) · Journal of Fungi

Antifungal resistance and susceptibilityImmunodeficiency and Autoimmune Disorders

Cited by 32

Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

Delforge, M., Patel, K., Eliason, L., Dhanda, D., Shi, L., Guo, S., Marshall, T. S., Arnulf, B., Cavo, M., Nooka, A., et al. (2024) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 31

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

Agha, M. E., Cohen, A. D., Madduri, D., Cohen, Y. C., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M.-S., Scheid, C., et al. (2021) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 30

Theranostics in Hematooncology

Buck, A. K., Serfling, S. E., Kraus, S., Samnick, S., Dreher, N., Higuchi, T., Rasche, L., Einsele, H., & Werner, R. A. (2023) · Journal of Nuclear Medicine

Radiopharmaceutical Chemistry and ApplicationsLymphoma Diagnosis and Treatment

Cited by 25

P899: REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASE

Dhakal, B., Einsele, H., Potluri, R., Schecter, J., Deraedt, W., Lendvai, N., Slaughter, A., Lonardi, C., Nair, S., He, J., et al. (2022) · HemaSphere

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 9

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.

Einsele, H., Cohen, A. D., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M.-S., Scheid, C., Schecter, J. M., De Braganca, K. C., et al. (2022) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 7

P-240: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare database

Dhakal, B., Einsele, H., Potluri, R., Schecter, J., Deraedt, W., Lendvai, N., Slaughter, A., Lonardi, C., Nair, S., He, J., et al. (2022) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 3

MM-464 LocoMMotion: a prospective, observational, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma–final analysis at 2-year follow-up

Moreau, P., Weisel, K., de Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Lindsey-Hill, J., Dytfeld, D., Angelucci, E., Vincent, L., et al. (2023) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1